OpenURL Connection Search - EBSCO

Connecting you to content on EBSCOhostUNIVERSITÄT DORTMUND

Select item for more details and to access through your institution.

Baricitinib in patients with moderate‐to‐severe atopic dermatitis and inadequate response to topical corticosteroids: results from two randomized monotherapy phase III trials.
Published in:
British Journal of Dermatology, 2020, v. 183, n. 2, p. 242, doi. 10.1111/bjd.18898
By:
- Simpson, E.L.;
- Lacour, J.‐P.;
- Spelman, L.;
- Galimberti, R.;
- Eichenfield, L.F.;
- Bissonnette, R.;
- King, B.A.;
- Thyssen, J.P.;
- Silverberg, J.I.;
- Bieber, T.;
- Kabashima, K.;
- Tsunemi, Y.;
- Costanzo, A.;
- Guttman‐Yassky, E.;
- Beck, L.A.;
- Janes, J.M.;
- DeLozier, A.M.;
- Gamalo, M.;
- Brinker, D.R.;
- Cardillo, T.
Publication type:
Article
A randomized phase 2b trial of baricitinib, an oral Janus kinase ( JAK) 1/JAK2 inhibitor, in patients with moderate-to-severe psoriasis.
Published in:
British Journal of Dermatology, 2016, v. 174, n. 6, p. 1266, doi. 10.1111/bjd.14403
By:
- Papp, K.A.;
- Menter, M.A.;
- Raman, M.;
- Disch, D.;
- Schlichting, D.E.;
- Gaich, C.;
- Macias, W.;
- Zhang, X.;
- Janes, J.M.
Publication type:
Article